Skip to main content
. 2016 Nov 15;2016:3681731. doi: 10.1155/2016/3681731

Table 1.

Demographics and clinical and pathological characteristics of patients undergoing TIPS.

Variable Overall Stenosis (n = 40) Nonstenosis (n = 321) P value HE (n = 86) Non-HE (n = 275) P value
Age (mean ± SD, years) 49.90 ± 11.34 50.45 ± 10.33 49.83 ± 11.7 0.747 50.37 ± 10.18 49.76 ± 11.69 0.661
MELD score 10.60 ± 3.11 13.05 ± 2.06 10.25 ± 3.05 <0.001 13.52 ± 2.22 9.68 ± 2.77 <0.001
  Bilirubin (μmol/L) 33.65 ± 66.83 40.38 ± 58.11 33.25 ± 30.23 <0.001 39.26 ± 50.14 40.15 ± 28.96 <0.001
  Creatinine (mg/dL) 0.82 ± 0.45 0.83 ± 0.41 0.81 ± 0.36 0.264 0.89 ± 0.31 0.80 ± 0.44 0.546
  INR 1.40 ± 0.32 1.46 ± 0.35 1.39 ± 0.28 0.864 1.45 ± 0.34 1.40 ± 0.29 0.901
Blood ammonia 82.70 ± 18.48 82.95 ± 19.22 82.67 ± 18.41 0.929 86.77 ± 2.05 81.43 ± 17.44 0.035
ALT (U/L) 45.87 ± 17.88 45.38 ± 16.66 45.93 ± 18.05 0.852 49.52 ± 19.98 44.73 ± 17.05 0.047
AST (U/L) 41.02 ± 14.77 43.05 ± 15.71 40.77 ± 14.65 0.358 42.74 ± 14.45 40.49 ± 14.85 0.217
PVP pre-TIPS 40.07 ± 3.25 43.18 ± 3.57 39.81 ± 3.12 <0.001 44.30 ± 2.34 38.75 ± 2.19 <0.001
PVP post-TIPS 11.03 ± 1.87 11.45 ± 2.23 10.98 ± 1.82 0.130 11.85 ± 1.80 10.77 ± 1.82 <0.001
PVP reduction 29.04 ± 3.42 30.73 ± 3.88 28.83 ± 3.30 0.001 32.45 ± 2.81 27.98 ± 2.85 <0.001
Gender
  Male (n/%) 237 (65.7) 24 (60.0) 213 (66.4) 0.425 54 (62.8) 183 (66.5) 0.552
  Female (n/%) 124 (34.3) 16 (40.0) 108 (33.6) 32 (37.2) 92 (33.5)
Inflammation grading
  G1-G2 235 (65.1) 17 (42.5) 218 (67.9) 0.001 41 (47.4) 194 (70.5) <0.001
  G3-G4 126 (34.9) 23 (57.5) 103 (32.1) 45 (52.3) 81 (29.5)
Fibrosis staging
  S1-S2 120 (33.2) 8 (20.0) 112 (34.9) 0.074 17 (19.8) 103 (37.5) 0.002
  S3-S4 241 (66.8) 32 (80.0) 209 (65.1) 69 (80.2) 172 (62.5)
HE occurrence Shunt restenosis occurrence
  Y 86 (23.8) 24 (60.0) 62 (19.3) <0.001 24 (27.9) 16 (5.8) <0.001
  N 275 (76.2) 16 (40.0) 259 (80.7) 62 (72.1) 259 (94.2)
Indication of TIPS
  Gastric variceal bleeding 301 (83.4) 35 (87.5) 266 (82.9) 0.865 74 (86.0) 227 (82.5) 0.785
  Refractory ascites 43 (11.9) 4 (10.0) 39 (12.1) 8 (9.3) 25 (12.7)
  Both symptoms 17 (4.7) 1 (2.5) 16 (5.0) 4 (4.7) 13 (4.8)
Child-Pugh classification
  A 207 (57.3) 18 (45.0) 189 (58.9) 0.164 50 (58.7) 157 (57.1) 0.875
  B 93 (25.8) 15 (37.5) 78 (24.3) 23 (26.7) 70 (25.5)
  C 61 (16.9) 7 (17.5) 54 (16.8) 13 (15.1) 48 (17.5)
Number of stents
  1 270 (74.8) 30 (75.0) 240 (74.8) 0.974 61 (70.9) 209 (76.0) 0.345
  2 91 (25.2) 10 (25.0) 81 (25.2) 25 (29.1) 66 (24.0)
Diameter of stent (mm)
  8 298 (82.5) 32 (80.0) 266 (82.9) 0.660 74 (86.0) 224 (81.5) 0.327
  10 63 (17.5) 8 (20.0) 55 (17.1) 12 (14.0) 51 (18.5)

TIPS: transjugular intrahepatic portosystemic shunt; MELD: model for end-stage liver disease; INR: international normalized ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PVP: portal vein pressure; G: grading; S: staging; HE: hepatic encephalopathy.